Thomson Reuters/Uni...
Health Care: Drugs
AVEO Pharmaceuticals Inc. (AVEO: NASDAQ)
$3.01 0.20 | 7.12%
05/17/13 - 04:00 PM ET
Portfolios with AVEO
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ProSeth Klarman - Baupost Group
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorBreakout Stocks Of The Week...
- ContributorHot Biotech Trades for Seco...
- Contributor10 Health-Care Stocks Outpe...
Latest AVEO Headlines from TheStreet
- Aveo Screwed Up But Its Kidney Cancer Drug Is Real 05.15.13 | 08:05 am
- 3 Health Care Stocks Under $10 to Watch 05.09.13 | 09:05 pm
- Bubble Fears Amid Relentless Market Climb 05.06.13 | 02:05 pm
- Fire Aveo's CEO for Incompetence and Arrogance Rivaling ImClone's Sam Waksal 05.06.13 | 12:05 pm
- Leaders of TheStreet's Drug Approval Contest 05.06.13 | 09:05 am
- Stock Futures Eye Rebound on ECB Stimulus, U.S. Data 05.02.13 | 08:05 am
- Aveo, Delcath FDA Panel Live Blog 05.02.13 | 07:05 am
- Why Aveo's Tivozanib Should Win FDA Approval 05.02.13 | 06:05 am
- AVEO Pharmaceuticals Enters Oversold Territory (AVEO) 04.30.13 | 12:04 pm
- Should Aveo Run Second Study of Kidney Cancer Drug, FDA Asks 04.30.13 | 09:04 am
Press Releases for AVEO
- AVEO Oncology To Present At The Barclays Global Healthcare Conference - Business Wire 03.06.13 | 06:03 am
- AVEO And Astellas Announce FDA Advisory Committee To Review Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma - Business Wire 02.27.13 | 06:02 am
- AVEO Oncology To Present At The 2013 RBC Capital Markets’ Healthcare Conference - Business Wire 02.20.13 | 06:02 am
- AVEO And Astellas Report Final Overall Survival Results From TIVO-1 - Business Wire 02.12.13 | 06:02 pm
- AVEO Oncology Announces Timing For Fourth Quarter And Year-End 2012 Financial Results Conference Call - Business Wire 01.31.13 | 06:01 am
- AVEO And Astellas Announce Presentations Of Tivozanib Clinical Data At 2013 ASCO Genitourinary Cancers Symposium - Business Wire 01.29.13 | 06:01 am
- AVEO Announces Closing Of Public Offering - Business Wire 01.24.13 | 06:01 am
- AVEO Announces Exercise Of Over-Allotment Option For Recent Public Offering - Business Wire 01.22.13 | 08:01 am
- AVEO Prices Public Offering Of Common Stock - Business Wire 01.17.13 | 09:01 am
- AVEO Announces Proposed Public Offering Of Common Stock - Business Wire 01.16.13 | 04:01 pm
Partner Headlines for AVEO
- UPDATE: Canaccord Genuity Downgrades AVEO Pharmaceuticals to Hold Following ODAC Meeting - Benzinga 05.03.13 | 09:05 am
- Pre-Market Most Active for Apr 30, 2013 : SIRI, MTU, SMFG, PFE, DCM, NTT, STM, NUAN, VOD, ANAD, AVEO, BBRY - NASDAQ 04.30.13 | 12:04 pm
- AVEO Pharmaceuticals Earnings: Here’s Why Shares are Down Now - Wall St. Cheat Sheet 04.29.13 | 10:04 am
- Thursday's BioPharma Trade Movers - Seeking Alpha 04.18.13 | 09:04 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.23.12 | 09:10 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 10.17.12 | 09:10 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 10.10.12 | 09:10 am
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seeking Alpha 05.25.12 | 08:05 pm
- 4 Compelling Alternatives To Vertex Pharma - Seeking Alpha 02.23.12 | 08:02 am
- 5 Stocks That Could Be Takeover Targets - Seeking Alpha 02.01.12 | 08:02 am
